Drug Trial Radar · NCT01623596
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
881
Actual
Start
Jun 8, 2012
Primary completion
Jul 13, 2015
Study completion Jul 13, 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
FingolimodDrug
Disease Modifying therapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant Retention Rate Over 12 MonthsTime frame: at 12 months
Locations
123 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Cullman, Alabama
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Sun City, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Sherwood, Arkansas
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Walnut Creek, California
Novartis Investigative Site
Basalt, Colorado
Novartis Investigative Site
Boulder, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Fairfield, Connecticut
Novartis Investigative Site
New London, Connecticut
Novartis Investigative Site
Dover, Delaware
Novartis Investigative Site
Atlantis, Florida
Novartis Investigative Site
Bradenton, Florida
Novartis Investigative Site
Delray Beach, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
North Palm Beach, Florida
Novartis Investigative Site
Plantation, Florida
Novartis Investigative Site
Pompano Beach, Florida
Novartis Investigative Site
Port Charlotte, Florida
Novartis Investigative Site
Port Orange, Florida
Novartis Investigative Site
Sarasota, Florida
Novartis Investigative Site
Sarasota, Florida
Novartis Investigative Site
St. Petersburg, Florida
Novartis Investigative Site
Tallahassee, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
West Palm Beach, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Columbus, Georgia
Novartis Investigative Site
Decatur, Georgia
Novartis Investigative Site
Suwanee, Georgia
Novartis Investigative Site
Flossmoor, Illinois
Novartis Investigative Site
Northbrook, Illinois
Novartis Investigative Site
Anderson, Indiana
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.